STOCK TITAN

Abeona (ABEO) Form 144 Discloses Insider Dispositions Totaling 64,708 Shares

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
144

Rhea-AI Filing Summary

Abeona Therapeutics (ABEO) Form 144: This notice shows an intended sale of 15,000 shares of common stock through Stifel Nicolaus with an aggregate market value of $110,358, scheduled approximately for 08/15/2025. The filer acquired 47,303 shares as restricted stock units on 06/05/2024 and indicates cash payment on 06/06/2025. Recent disclosed sales by the same person total 64,708 shares for gross proceeds of $278,087.63 across trades on 06/06/2025, 07/09/2025, and 07/22/2025.

The form is a routine Section 144 notice required for proposed sales by an affiliate and includes the filer’s representation that no undisclosed material adverse information is known. The shares to be sold represent a small fraction of the issuer’s reported 51,278,539 outstanding shares.

Positive

  • Compliance and transparency: The filer provided required broker, acquisition and sale details in a live Form 144 filing.

Negative

  • Insider sales activity: The filer sold 64,708 shares in the past three months and proposes to sell an additional 15,000 shares, which may be perceived negatively by some investors.

Insights

TL;DR: Insider sales disclosed: routine Section 144 filing showing modest ongoing dispositions relative to total shares outstanding.

The filing reports a planned sale of 15,000 shares and prior sales totaling 64,708 shares producing $278,087.63 in proceeds. Relative to 51,278,539 shares outstanding, these transactions amount to roughly 0.13% of the float, suggesting limited direct dilution or corporate impact. The disclosure of acquisition as restricted stock units and subsequent cash payment is consistent with typical post-vesting liquidity actions by insiders. Investors should note the pattern of serial sales but the absolute scale appears immaterial to company capital structure based on the numbers provided in this filing.

TL;DR: Filing meets disclosure obligations; the insider affirms no undisclosed material information but does not indicate a 10b5-1 plan.

The Form 144 provides required broker, transaction and acquisition details and includes the signed representation regarding material information. The document does not state adoption of a trading plan or provide a plan adoption date. The pattern of sales (06/06, 07/09, 07/22/2025 and proposed 08/15/2025) reflects active post-vesting sales of RSUs. From a governance standpoint, the filing is compliant and transparent; absence of an explicit 10b5-1 declaration in this notice is a neutral governance signal based solely on the content presented.

144: Filer Information

144: Issuer Information

144: Securities Information



Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold


* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

144: Remarks and Signature

FAQ

What does the ABEO Form 144 disclose?

The filing discloses a proposed sale of 15,000 common shares (aggregate value $110,358) and prior sales of 64,708 shares for $278,087.63.

Who is selling ABEO shares according to the filing?

The seller named in the prior sales is Joseph Vazzano and the proposed sale is to be handled by Stifel Nicolaus & Company Inc.

When were the acquired shares received and how were they acquired?

The shares to be sold were acquired as Restricted Stock Units on 06/05/2024, with 47,303 units listed and payment recorded as cash on 06/06/2025.

What is the approximate date for the proposed sale and on which exchange?

The proposed sale is approximately 08/15/2025 on Nasdaq via Stifel Nicolaus.

How large are these sales relative to ABEO’s outstanding shares?

The filing states 51,278,539 shares outstanding; the proposed 15,000-share sale is a small fraction (~0.03%) of outstanding shares.
Abeona Therapeut

NASDAQ:ABEO

ABEO Rankings

ABEO Latest News

ABEO Latest SEC Filings

ABEO Stock Data

295.34M
48.61M
5.78%
73.58%
17.61%
Biotechnology
Pharmaceutical Preparations
Link
United States
CLEVELAND